{
    "id": 2588,
    "fullName": "CBFB - MYH11",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CBFB-MYH11 results from the fusion of CBFB and MYH11, resulting in repression of core binding factor function, and works synergistically with other genes to induce leukemogenesis (PMID: 15044690). CBFB-MYH11 has been identified in acute myeloid leukemia (PMID: 20164853).",
            "references": [
                {
                    "id": 9831,
                    "pubMedId": 15044690,
                    "title": "Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15044690"
                },
                {
                    "id": 16413,
                    "pubMedId": 20164853,
                    "title": "AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20164853"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 865,
        "geneSymbol": "CBFB",
        "terms": [
            "CBFB",
            "PEBP2B"
        ]
    },
    "variant": "CBFB - MYH11",
    "createDate": "11/18/2014",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4629,
                "geneSymbol": "MYH11",
                "terms": [
                    "MYH11",
                    "AAT4",
                    "FAA4",
                    "SMHC",
                    "SMMHC"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 2457,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AI-10-49 induced apoptosis and prevented colony formation of human leukemia cells harboring the CBFB-MYH11 fusion (PMID: 25678665).",
            "molecularProfile": {
                "id": 2435,
                "profileName": "CBFB - MYH11"
            },
            "therapy": {
                "id": 2859,
                "therapyName": "AI-10-49",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3100,
                    "pubMedId": 25678665,
                    "title": "Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBF\u03b2-SMMHC delays leukemia in mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25678665"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18055,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "CBFB-MYH11 fusions (inv(16)(p13.1q22) or t(16;16)(p13.1;q22)) are associated with a favorable prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 2435,
                "profileName": "CBFB - MYH11"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1386,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, acute myeloid leukemia patients harboring CBFB-MYH11 fusions resulting from a t(16;16)(p13;q22) translocation demonstrated a complete remission rate of 100% (6/6), and patients patients harboring CBFB-MYH11 resulting from inv(16)(p13q22) demonstrated a complete remission rate of 93% (51/61) following treatment with a chemotherapy regimen that included high-dose Cytosar-U (cytarabine) and Fludara (fludarabine) (PMID: 22228403).",
            "molecularProfile": {
                "id": 2435,
                "profileName": "CBFB - MYH11"
            },
            "therapy": {
                "id": 2294,
                "therapyName": "Cytarabine + Fludarabine",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1126,
                    "pubMedId": 22228403,
                    "title": "Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22228403"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2435,
            "profileName": "CBFB - MYH11",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}